These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 37337526)

  • 1. A Bayesian Reanalysis of a Trial of Psilocybin versus Escitalopram for Depression.
    Nayak SM; Bari BA; Yaden DB; Spriggs MJ; Rosas FE; Peill JM; Giribaldi B; Erritzoe D; Nutt DJ; Carhart-Harris R
    Psychedelic Med (New Rochelle); 2023 Mar; 1(1):18-26. PubMed ID: 37337526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trial of Psilocybin versus Escitalopram for Depression.
    Carhart-Harris R; Giribaldi B; Watts R; Baker-Jones M; Murphy-Beiner A; Murphy R; Martell J; Blemings A; Erritzoe D; Nutt DJ
    N Engl J Med; 2021 Apr; 384(15):1402-1411. PubMed ID: 33852780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A critical evaluation of QIDS-SR-16 using data from a trial of psilocybin therapy versus escitalopram treatment for depression.
    Weiss B; Erritzoe D; Giribaldi B; Nutt DJ; Carhart-Harris RL
    J Psychopharmacol; 2023 Jul; 37(7):717-732. PubMed ID: 37122239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.
    Davis AK; Barrett FS; May DG; Cosimano MP; Sepeda ND; Johnson MW; Finan PH; Griffiths RR
    JAMA Psychiatry; 2021 May; 78(5):481-489. PubMed ID: 33146667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression.
    Szigeti B; Weiss B; Rosas FE; Erritzoe D; Nutt D; Carhart-Harris R
    Psychol Med; 2024 Jun; 54(8):1717-1724. PubMed ID: 38247730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased global integration in the brain after psilocybin therapy for depression.
    Daws RE; Timmermann C; Giribaldi B; Sexton JD; Wall MB; Erritzoe D; Roseman L; Nutt D; Carhart-Harris R
    Nat Med; 2022 Apr; 28(4):844-851. PubMed ID: 35411074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression.
    Murphy R; Kettner H; Zeifman R; Giribaldi B; Kartner L; Martell J; Read T; Murphy-Beiner A; Baker-Jones M; Nutt D; Erritzoe D; Watts R; Carhart-Harris R
    Front Pharmacol; 2021; 12():788155. PubMed ID: 35431912
    [No Abstract]   [Full Text] [Related]  

  • 8. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.
    Carhart-Harris RL; Bolstridge M; Rucker J; Day CM; Erritzoe D; Kaelen M; Bloomfield M; Rickard JA; Forbes B; Feilding A; Taylor D; Pilling S; Curran VH; Nutt DJ
    Lancet Psychiatry; 2016 Jul; 3(7):619-27. PubMed ID: 27210031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
    Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
    Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial.
    von Rotz R; Schindowski EM; Jungwirth J; Schuldt A; Rieser NM; Zahoranszky K; Seifritz E; Nowak A; Nowak P; Jäncke L; Preller KH; Vollenweider FX
    EClinicalMedicine; 2023 Feb; 56():101809. PubMed ID: 36636296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial.
    Kim JM; Bae KY; Stewart R; Jung BO; Kang HJ; Kim SW; Shin IS; Hong YJ; Kim JH; Shin HY; Kang G; Ahn Y; Kim JK; Jeong MH; Yoon JS
    J Clin Psychiatry; 2015 Jan; 76(1):62-8. PubMed ID: 25375836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Psilocybin compared with escitalopram for depression].
    Strous JFM
    Ned Tijdschr Geneeskd; 2022 Jan; 166():. PubMed ID: 35138714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of psilocybin versus escitalopram on rumination and thought suppression in depression.
    Barba T; Buehler S; Kettner H; Radu C; Cunha BG; Nutt DJ; Erritzoe D; Roseman L; Carhart-Harris R
    BJPsych Open; 2022 Sep; 8(5):e163. PubMed ID: 36065128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects.
    Becker AM; Holze F; Grandinetti T; Klaiber A; Toedtli VE; Kolaczynska KE; Duthaler U; Varghese N; Eckert A; Grünblatt E; Liechti ME
    Clin Pharmacol Ther; 2022 Apr; 111(4):886-895. PubMed ID: 34743319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Difference in the regulation of biological rhythm symptoms of Major depressive disorder between escitalopram and mirtazapine.
    Huang H; Wang F; Chen Y; Kong S; Huang Q; Lyu D; Yang W; Wei Z; Qian N; Zhang M; Wu C; Zhao J; Cao L; Wu Z; Peng D; Fang Y; Hong W
    J Affect Disord; 2022 Jan; 296():258-264. PubMed ID: 34624810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guidance on the conversion of the Chinese versions of the Quick Inventory of Depressive Symptomatology-Self-Report (C-QIDS-SR) and the Montgomery-Asberg Scale (C-MADRS) in Chinese patients with major depression.
    Liu J; Xiang YT; Lei H; Wang Q; Wang G; Ungvari GS; Morris DW; Zhu XZ; Lai KY; Zhong BL; Wong SY; Zhang L; Zhang Q; Zou YC; Xiao L; Zhao Q; Li Y; Wu J; Zhang GF; Chiu HF
    J Affect Disord; 2014 Jan; 152-154():530-3. PubMed ID: 24144585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting the outcome of psilocybin treatment for depression from baseline fMRI functional connectivity.
    Copa D; Erritzoe D; Giribaldi B; Nutt D; Carhart-Harris R; Tagliazucchi E
    J Affect Disord; 2024 May; 353():60-69. PubMed ID: 38423367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current Understanding on Psilocybin for Major Depressive Disorder: A Review Focusing on Clinical Trials.
    Wang SM; Kim S; Choi WS; Lim HK; Woo YS; Pae CU; Bahk WM
    Clin Psychopharmacol Neurosci; 2024 May; 22(2):222-231. PubMed ID: 38627070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simvastatin add-on to escitalopram in patients with comorbid obesity and major depression (SIMCODE): study protocol of a multicentre, randomised, double-blind, placebo-controlled trial.
    Otte C; Chae WR; Nowacki J; Kaczmarczyk M; Piber D; Roepke S; Märschenz S; Lischewski S; Schmidt S; Ettrich B; Grabe HJ; Hegerl U; Hinkelmann K; Hofmann T; Janowitz D; Junghanns K; Kahl KG; Klein JP; Krueger THC; Leicht G; Prvulovic D; Reif A; Schoettle D; Strauss M; Westermair A; Friede T; Gold SM
    BMJ Open; 2020 Dec; 10(12):e040119. PubMed ID: 33262189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.